US Patent Application No: 2012/0189,542

Number of patents in Portfolio can not be more than 2000

Anti-CD19 Antibodies

ALSO PUBLISHED AS: 8337840

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOMEDICS, INC.MORRIS PLAINS, NJ269

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Goldenberg, David M Mendham, NJ 480 2248
Hansen, Hans J Picayune, MS 274 1726
Qu, Zhengxing Warren, NJ 123 439

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Full Text

 
loading....